Biovail (BVF) Reaches Settlement Agreement with OSC Staff
More News related to BVF
- Biovail Announces Closing of Acquisition of Worldwide Rights to Tetrabenazine
- TD Newcrest Upgrades Biovail (BVF) to Action List Buy
- Biovail (BVF) Announces New Increased Revolving Credit Facility
- Biovail Announces New Increased Revolving Credit Facility
- Biovail Announces Pricing of Offering of US$300 Million Senior Convertible Notes due 2014
Biovail Corporation (NYSE: BVF) today announced it has reached a settlement agreement with the Staff of the Ontario Securities Commission in respect of an investigation of the Company and certain former officers. The settlement agreement, which is subject to approval by the OSC, will be considered at a hearing that has been scheduled for January 9, 2009.
The investigation related to specific accounting and financial disclosure practices, as previously disclosed, that occurred between 2001 and March 2004 and resulted in a Statement of Allegations by the OSC in March 2008. Terms of the settlement agreement are confidential and will be made public if and when approved by the OSC.
Biovail Corporation, a pharmaceutical company, engages in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products utilizing various drug-delivery technologies in the United States and Canada.
Related Categories
Corporate NewsStocks Mentioned
+16.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
